Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty

Thrombosis Research

Volumn 130, Issue 2, 2012, Pages 147-151

  Eriksson, Bengt I ^a   Rosencher, Nadia ^b   Friedman, Richard J ^c   Homering, Martin ^d   Dahl, Ola E ^e  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b université Paris Cité   (France)

^c Roper St Francis Healthcare   (United States)

^d BAYER PHARMA AG   (Germany)

^e Elverum Central Hospital   (Norway)

Author keywords

Drug interactions; Non steroidal anti inflammatory agents; Platelet function inhibitors; Rivaroxaban; Total hip arthroplasty; Total knee arthroplasty

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RIVAROXABAN;

ADULT; BLEEDING TIME; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; KNEE ARTHROPLASTY; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE FUNCTION; TOTAL HIP PROSTHESIS; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, KNEE; ASPIRIN; DRUG INTERACTIONS; ENOXAPARIN; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PLATELET AGGREGATION INHIBITORS; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84864409896     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.12.005     Document Type: Conference Paper

References (22)

1. W.H. Geerts, D. Bergqvist, G.F. Pineo, J.A. Heit, C.M. Samama, and M.R. Lassen Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 2008 381S 453S (Pubitemid 351894916)
2. J.I. Weitz, J. Hirsh, and M.M. Samama New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 2008 234S 256S (Pubitemid 351892968)
3. B.I. Eriksson, L.C. Borris, R.J. Friedman, S. Haas, M.V. Huisman, and A.K. Kakkar Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2008 2765 2775 (Pubitemid 351930851)
4. A.K. Kakkar, B. Brenner, O.E. Dahl, B.I. Eriksson, P. Mouret, and J. Muntz Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Lancet 372 2008 31 39
5. M.R. Lassen, W. Ageno, L.C. Borris, J.R. Lieberman, N. Rosencher, and T.J. Bandel Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2008 2776 2786 (Pubitemid 351930852)
6. A.G.G. Turpie, M.R. Lassen, B.L. Davidson, K.A. Bauer, M. Gent, and L.M. Kwong Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Lancet 373 2009 1673 1680
7. L.A. García Rodríguez, C. Cattaruzzi, M.G. Troncon, and L. Agostinis Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs Arch Intern Med 158 1998 33 39 (Pubitemid 28070443)
8. D.Y. Graham, and F.K. Chan NSAIDs, risks, and gastroprotective strategies: current status and future Gastroenterology 134 2008 1240 1246 (Pubitemid 351451996)
9. C.B. Mantilla, T.T. Horlocker, D.R. Schroeder, D.J. Berry, and D.L. Brown Frequency of myocardial infarction, pulmonary embolism, deep venous thrombosis, and death following primary hip or knee arthroplasty Anesthesiology 96 2002 1140 1146 (Pubitemid 34462575)
10. American College of Rheumatology Subcommittee on Osteoarthritis The American College of Rheumatology Clinical Guidelines: Recommendations for the Medical Management of Osteoarthritis of the Hip and Knee Arthritis Rheum 43 2000 1905 1915
11. F. Wolfe, S. Zhao, and N. Lane Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia Arthritis Rheum 43 2000 378 385 (Pubitemid 30395747)
12. H.B. Fischer, and C.J. Simanski A procedure-specific systematic review and consensus recommendations for analgesia after total hip replacement Anaesthesia 60 2005 1189 1202 (Pubitemid 41762841)
13. H.B. Fischer, C.J. Simanski, C. Sharp, F. Bonnet, F. Camu, and E.A. Neugebauer A procedure-specific systematic review and consensus recommendations for postoperative analgesia following total knee arthroplasty Anaesthesia 63 2008 1105 1123
14. S.E. Gabriel, L. Jaakkimainen, and C. Bombardier Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis Ann Intern Med 115 1991 787 796
15. S. Derry, and Y.K. Loke Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis BMJ 321 2000 1183 1187
16. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf Rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen Br J Clin Pharmacol 63 2007 469 476 (Pubitemid 46426627)
17. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - are not affected by aspirin J Clin Pharmacol 46 2006 981 990 (Pubitemid 44215062)
18. J.W. Eikelboom, and J. Hirsh Combined antiplatelet and anticoagulant therapy: clinical benefits and risks J Thromb Haemost 5 Suppl. 1 2007 255 263
19. A.G.G. Turpie, W.D. Fisher, K.A. Bauer, L.M. Kwong, M.W. Irwin, and P. Kälebo BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study J Thromb Haemost 3 2005 2479 2486 (Pubitemid 41727165)
20. B.I. Eriksson, L. Borris, O.E. Dahl, S. Haas, M.V. Huisman, and A.K. Kakkar Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement J Thromb Haemost 4 2006 121 128
21. B.I. Eriksson, A.A. Kurth, R.J. Friedman, J.M. Schnee, A. Clemens, and H. Noack Risk of bleeding with dabigatran etexilate in patients undergoing major orthopaedic surgery is not increased by concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid J Thromb Haemost 7 2009 374 PP-MO-167
22. P.C. Wong, C.A. Watson, and E.J. Crain Arterial antithrombotic and bleeding time effects of apixaban, a direct Factor Xa inhibitor, in combination with antiplatelet therapy in rabbits J Thromb Haemost 6 2008 1736 1741